• About Us
  • Contact Us
  • Advertise
  • Privacy Policy
  • Guest Post
No Result
View All Result
Digital Phablet
  • Home
  • NewsLatest
  • Technology
    • Education Tech
    • Home Tech
    • Office Tech
    • Fintech
    • Digital Marketing
  • Social Media
  • Gaming
  • Smartphones
  • AI
  • Reviews
  • Interesting
  • How To
  • Home
  • NewsLatest
  • Technology
    • Education Tech
    • Home Tech
    • Office Tech
    • Fintech
    • Digital Marketing
  • Social Media
  • Gaming
  • Smartphones
  • AI
  • Reviews
  • Interesting
  • How To
No Result
View All Result
Digital Phablet
No Result
View All Result

Home » Kangtai Halts $400M Vaccine JV with AstraZeneca in Beijing

Kangtai Halts $400M Vaccine JV with AstraZeneca in Beijing

Fahad Khan by Fahad Khan
February 9, 2026
in Business
Reading Time: 2 mins read
A A
Kangtai Halts $400M Vaccine JV with AstraZeneca in Beijing
ADVERTISEMENT

Select Language:

Kangtai Biological Products announced it has canceled its plan to establish a joint venture with a UK-Swedish pharmaceutical company in Beijing, which was slated to involve an investment of approximately USD 400 million. The decision was made due to significant market shifts and industry downturn risks.

ADVERTISEMENT

The company stated that halting this project would not have a substantial impact on its current operations, financial health, or future strategic plans. It emphasized that no actual investments had been made into the joint venture at this point.

Moving forward, Kangtai will focus on optimizing its internal and external resources, strengthening its global presence, and pursuing sustainable and steady growth.

Earlier last year, the company revealed plans to form a 50:50 joint venture with the international firm in the Beijing Economic-Technological Development Area. This collaboration aimed to develop innovative vaccines, including the investigational combination shot IVX-A12 for respiratory syncytial virus and human metapneumovirus, targeting the Chinese market. The facility would have marked the first vaccine manufacturing base in China for the international partner.

ADVERTISEMENT

Despite the absence of approved vaccines for RSV or hMPV in China, and a lack of effective antiviral drugs, demand for certain pediatric vaccines has slowed amid declining birth rates. Additionally, the adult vaccination sector remains in its nascent stages, requiring ongoing development and adaptation, industry experts noted.

Data from the China Chamber of Commerce for Import and Export of Medicines and Health Products showed a decline in vaccine batches issued and imports last year. Many multinational pharmaceutical companies operating in China scaled back or temporarily suspended vaccine imports to manage existing inventories.

Kangtai projected a sharp decrease in net profit for last year, estimating a drop of 64 to 76 percent, to between CNY 49 million and CNY 73 million (USD 7.1 million to USD 10.5 million).

Meanwhile, the international pharmaceutical giant continues to bolster its investments in China, announcing on Jan. 29 a plan to invest over USD 15 billion over the next five years to expand production facilities and research capabilities across the country.

As of 1:45 p.m. today, Kangtai’s stock traded at CNY 15.53 (USD 2.24), a slight decline of 0.3 percent in Shenzhen.

ChatGPT ChatGPT Perplexity AI Perplexity Gemini AI Logo Gemini AI Grok AI Logo Grok AI
Google Banner
ADVERTISEMENT
Fahad Khan

Fahad Khan

A Deal hunter for Digital Phablet with a 8+ years of Digital Marketing experience.

Related Posts

All You Need to Know About Collars in Mewgenics: Completing and Solving
Gaming

All You Need to Know About Collars in Mewgenics: Completing and Solving

February 10, 2026
Nio to Recall 245,000+ EVs Over Software Glitch
Business

Nio to Recall 245,000+ EVs Over Software Glitch

February 10, 2026
Ghislaine Maxwell Asks Trump for Clemency Ahead of Testimony
News

Ghislaine Maxwell Asks Trump for Clemency Ahead of Testimony

February 10, 2026
PS5 Wolverine Release Date Closer, PS Store Narrowly Targets Window
Gaming

PS5 Wolverine Release Date Closer, PS Store Narrowly Targets Window

February 10, 2026
Next Post
IQiyi Launches China’s First Immersive Video-Themed Park in Yangzhou

IQiyi Launches China’s First Immersive Video-Themed Park in Yangzhou

  • About Us
  • Contact Us
  • Advertise
  • Privacy Policy
  • Guest Post

© 2026 Digital Phablet

No Result
View All Result
  • Home
  • News
  • Technology
    • Education Tech
    • Home Tech
    • Office Tech
    • Fintech
    • Digital Marketing
  • Social Media
  • Gaming
  • Smartphones

© 2026 Digital Phablet